X-linked clonality testing: interpretation and limitations

被引:42
作者
Chen, George L. [1 ]
Prchal, Josef T.
机构
[1] Stanford Univ, Sch Med, Div Blood & Marrow Transplant, Palo Alto, CA 94304 USA
[2] Univ Utah, Sch Med, Div Hematol, Dept Med, Salt Lake City, UT USA
关键词
D O I
10.1182/blood-2006-09-018655
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clonality often defines the diseased state in hematology. Clonal cells are genetically homogenous and derived from the same precursor; their detection is based on genotype or phenotype. Genotypic clonality relies on somatic mutations to mark the clonal population. Phenotypic clonality identifies the clonal population by the expression pattern of surrogate genes that track the clonal process. The most commonly used phenotypic clonallity methods are based on the X-chromosome inactivation principle. Clonality detection based on X-chromosome inactivation patterns (XCIP) requires discrimination of the active from the inactive X chromosome and differentiation of each X chromosome's parental origin. Detection methods are based on detection of X-chromosome sequence polymorphisms identified by protein isoforms, transcribed mRNA, and methylation status. Errors in interpreting clonality tests arise from stochastic, genetic, and cell selection pressures on the mechanism of X inactivation. Progressive X-chromosome skewing has recently been suggested by XCIP clonality studies in aging hematopoietic cells. This has led to new insights into the pathophysiology of X-linked and autoimmune disorders. Other research applications include combining XCIP clonality testing with genetic clonality testing to identify clonal populations with yet-to-be-discovered genetic changes.
引用
收藏
页码:1410 / 1419
页数:10
相关论文
共 85 条
  • [1] An X chromosome gene regulates hematopoietic stem cell kinetics
    Abkowitz, JL
    Taboada, M
    Shelton, GH
    Catlin, SN
    Guttorp, P
    Kiklevich, JV
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) : 3862 - 3866
  • [2] POLYCYTHEMIA-VERA - STEM-CELL AND PROBABLE CLONAL ORIGIN OF DISEASE
    ADAMSON, JW
    FIALKOW, PJ
    MURPHY, S
    PRCHAL, JF
    STEINMANN, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (17) : 913 - 916
  • [3] COLONIC VILLOUS ADENOMA - MONOCLONAL ORIGIN
    ADOLPHSON, CC
    PRCHAL, JT
    CARROLL, AJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (06): : 829 - 830
  • [4] ALLEN RC, 1992, AM J HUM GENET, V51, P1229
  • [5] Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
    Antonioli, E
    Guglielmelli, P
    Pancrazzi, A
    Bogani, C
    Verrucci, M
    Ponziani, V
    Longo, G
    Bosi, A
    Vannucchi, AM
    [J]. LEUKEMIA, 2005, 19 (10) : 1847 - 1849
  • [6] Bacher CP, 2006, NAT CELL BIOL, V8, P293, DOI 10.1038/ncb1365
  • [7] Clinical impact of molecular diagnostics in low-grade lymphoma
    Bahloul, M
    Asnafi, V
    Macintyre, E
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (01) : 97 - 111
  • [8] Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender-related genes and the X-chromosome
    Barbesino, G
    Tomer, Y
    Concepcion, ES
    Davies, TF
    Greenberg, DA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) : 3290 - 3295
  • [9] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [10] Belmont JW, 1996, AM J HUM GENET, V58, P1101